ClinicalTrials.gg

Program

ONO-2808

A development code.

Its studies are mostly in Multiple System Atrophy · Neurodegenerative Diseases, led by Ono Pharmaceutical.

Furthest: phase 3, since Sep 13, 20263 company-led studies, 2 open or runningNext primary completion: Oct 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical32 open or runningphase 3since Sep 13, 2026Oct 1, 2020Oct 2029phase 3 · NCT07825402

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2020First study: phase 1 study in Neurodegenerative DiseasesFirst studyNCT04578028 · 94 enrolled · United Kingdom
  2. Jun 7, 2023Phase 2 study in Multiple System AtrophyNCT05923866 · 92 enrolled · United States, Japan
  3. Sep 13, 2026Phase 3 study in Multiple System AtrophyPhase 3 reachedNCT07825402 · 486 planned

Ahead

  1. Oct 2029Primary completion: phase 3 study in Multiple System AtrophyNCT07825402

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07825402Multiple System Atrophy3Not yet recruitingOct 2029486
NCT05923866Multiple System Atrophy · United States, Japan2Active, not recruitingSep 15, 202592
NCT04578028Neurodegenerative Diseases · United Kingdom1CompletedAug 26, 202194

How it is read

Names in the registry

  • “ONO-2808”, 3 entries

Codes read as this program: ONO2808.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.